학술논문
Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey
Document Type
article
Author
Bello, Aminu K; Levin, Adeera; Lunney, Meaghan; Osman, Mohamed A; Ye, Feng; Ashuntantang, Gloria E; Bellorin-Font, Ezequiel; Benghanem Gharbi, Mohammed; Davison, Sara N; Ghnaimat, Mohammad; Harden, Paul; Htay, Htay; Jha, Vivekanand; Kalantar-Zadeh, Kamyar; Kerr, Peter G; Klarenbach, Scott; Kovesdy, Csaba P; Luyckx, Valerie A; Neuen, Brendon L; O'Donoghue, Donal; Ossareh, Shahrzad; Perl, Jeffrey; Rashid, Harun Ur; Rondeau, Eric; See, Emily; Saad, Syed; Sola, Laura; Tchokhonelidze, Irma; Tesar, Vladimir; Tungsanga, Kriang; Turan Kazancioglu, Rumeyza; Wang, Angela Yee-Moon; Wiebe, Natasha; Yang, Chih-Wei; Zemchenkov, Alexander; Zhao, Ming-Hui; Jager, Kitty J; Caskey, Fergus; Perkovic, Vlado; Jindal, Kailash K; Okpechi, Ikechi G; Tonelli, Marcello; Feehally, John; Harris, David C; Johnson, David W
Source
Subject
Language
Abstract
ObjectiveTo determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis and transplantation) and conservative kidney management.DesignInternational cross sectional survey.SettingInternational Society of Nephrology (ISN) survey of 182 countries from July to September 2018.ParticipantsKey stakeholders identified by ISN's national and regional leaders.Main outcome measuresMarkers of national capacity to deliver core components of kidney replacement therapy and conservative kidney management.ResultsResponses were received from 160 (87.9%) of 182 countries, comprising 97.8% (7338.5 million of 7501.3 million) of the world's population. A wide variation was found in capacity and structures for kidney replacement therapy and conservative kidney management-namely, funding mechanisms, health workforce, service delivery, and available technologies. Information on the prevalence of treated end stage kidney disease was available in 91 (42%) of 218 countries worldwide. Estimates varied more than 800-fold from 4 to 3392 per million population. Rwanda was the only low income country to report data on the prevalence of treated disease; 5 (